Radiotherapy & Oncology
Volume 95, Issue 2 , Pages 225-228 , May 2010

Radiotherapy in early stage Hodgkin’s lymphoma: The importance of volume and treatment position

Received 18 May 2009 ,Revised 14 December 2009 ,Accepted 23 January 2010.

References 

  1. Noordijk E, Thomas J, Fermé C et al. First results of the EORTC–GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favourable and unfavourable early stage Hodgkin’s lymphoma. In: 41st Annual meeting of the american society of clinical oncology. J Clin Oncol 2005;23:651S [abstract 6505].
  2. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomised comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22:15–18
  3. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose–response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin’s disease. J Clin Oncol. 1997;15:2275–2287
  4. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357:1916–1927
  5. Noordijk EM, Carde P, Mandard AM, et al. Preliminary results of the EORTC–GPMC controlled clinical trial H7 in early stage Hodgkin’s disease. Ann Oncol. 1994;5:107–112
  6. The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiafragmatic stage I/II Hodgkin’s lymphoma. EORTC 20051, Lymphoma Group, 2005.
  7. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270–277
  8. Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC–GELA lymphoma group guidelines. Radiother Oncol. 2008;88:202–210
  9. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–3439
  10. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–2108
  11. Hancock SL, Tucker MA, Hoppe RT, et al. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–1955
  12. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst. 2003;95:971–980
  13. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst. 1995;87:1530–1537
  14. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–1437
  15. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002;94:182–192
  16. Boice JD. Radiation and breast carcinogenesis. Med Pediatr Oncol. 2001;36:508–513
  17. Hurkmans CW, Borger JH, van Giersbergen A, et al. Implementation of a forearm support to reduce the amount of irradiated lung and heart in radiation therapy of the breast. Radiother Oncol. 2001;61:193–196
  18. Canney PA, Deehan C, Glegg M, Dickson J. Reducing cardiac dose in post-operative irradiation of breast cancer patients: the relative importance of patient positioning and CT scan planning. Br J Radiol. 1999;72:986–993
  19. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?. IJROBP. 2006;64:218–226
  20. Goodman KA, Toner S, Hunt M, et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. IJROBP. 2005;62:198–206
  21. Nieder C, Schill S, Kneschaurek P, Molls M. Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts. Radiother Oncol. 2007;92:301–307

PII: S0167-8140(10)00059-9

doi: 10.1016/j.radonc.2010.01.008

Radiotherapy & Oncology
Volume 95, Issue 2 , Pages 225-228 , May 2010

Article Tools